The UK presents a valuable market opportunity for US medical device manufacturers, underpinned by a well-established healthcare system and a commitment to innovation. However, the UK’s post-Brexit regulatory framework introduces distinct challenges that often catch non-UK manufacturers off guard, particularly those unfamiliar with the Medicines and Healthcare products Regulatory Agency (MHRA) and its evolving requirements.
Explore five of the most common obstacles that US-based device companies face when entering the UK market, with a focus on regulatory misalignment, documentation errors, and compliance oversights. By understanding these challenges in advance, firms can streamline approval pathways and mitigate risk.
1. Misalignment with MHRA Approval Process
The MHRA established a sovereign regulatory system following the UK’s withdrawal from the European Union. US manufacturers often assume this process mirrors the FDA’s 510(k) or PMA procedures. However, the UK’s current framework, based on the UK Medical Devices Regulations 2023 (as amended), actually introduces key procedural and documentation differences.
One of the most significant changes is the requirement for UKCA (UK Conformity Assessed) marking in Great Britain, replacing the EU CE mark. While CE-marked products may continue to be accepted during a defined transition period, manufacturers must prepare for full UKCA conformity from 2028 onwards.
Products classified as Class IIb and III generally require review by a UK-Approved Body, while Class 1 devices may follow a self-certification pathway, provided certain conditions are met.
US firms commonly experience delays when attempting to reuse FDA submission criteria, documentation formatting, or evidence thresholds. In some cases, a device’s classification under UK MDR places it in a higher risk category than under FDA guidelines, triggering a more burdensome conformity assessment route.
It is also crucial to note that UK conformity requirements apply specifically to the Great Britain market. Devices placed in Northern Ireland must still comply with EU MDR and bear the CE mark, unless the manufacturer qualifies for dual marking under current UK-EU arrangements. This adds more complexity for US companies looking to distribute across the whole of the UK.
Manufacturers must also find their way by appointing a UK-based Responsible Person and registering their devices with the MHRA before marketing. Without prior experience in the UK system, companies often underestimate the time and resources required to fulfil these obligations.
Related Reading: New Post-Market Surveillance Requirements for Medical Devices UK in 2025
2. Frequent Submission Errors and Documentation Gaps
Common MHRA submission errors remain one of the leading causes of delayed UK market entry for overseas manufacturers. These issues are particularly pronounced among companies accustomed to FDA procedures and US documentation structures.
According to MHRA guidance, recurring submission issues include:
- Omission of valid Declarations of Conformity for UKCA or CE marking (where applicable during the transition period).
- Failure to designate a UK-based Responsible Person (RP) is a legal requirement for all non-UK manufacturers.
- Submission of EU-format technical files or outdated CE documentation instead of UK-specific formats.
- Incorrect device classification leading to misapplication of conformity assessment pathways.
- Absence of a valid UK-based address for the manufacturer or RP.
- Inaccurate product descriptions or incomplete supporting documentation.
These documentation gaps delay registration and increase the likelihood of regulatory scrutiny and potential non-compliance enforcement. The MHRA may request further evidence or clarification, suspending device placement on the market until issues are resolved.
In many cases, US firms lack internal resources and are not familiar with the structure and language of UK technical documentation. Terms, layouts, and evidentiary standards differ significantly from FDA expectations. The submission dossier must clearly demonstrate compliance with UK MDR and applicable standards such as ISO 13485, incorporating risk assessments, labelling information, and clinical data in the correct format.
Companies are strongly advised to engage in a pre-submission review process and seek regulatory consultancy where in-house experience is limited. Proactive planning reduces the risk of rejection and accelerates the path to market.
3. Inadequate Post-Market Surveillance Systems
Post-market obligations under the UK MDR are often underestimated by US manufacturers focused solely on market entry. While FDA-regulated post-approval processes may be familiar to these firms, the MHRA imposes distinct expectations for post-market surveillance (PMS) that require dedicated operational planning.
Manufacturers are expected to maintain robust PMS systems, which include:
- UK-specific PMS plans are appropriate to the device class and risk profile.
- Routine trend reporting and analysis of complaints, adverse events, and product performance.
- Vigilance reporting of serious incidents through the MHRA’s MORE portal
- Maintenance and periodic updating of technical documentation based on PMS findings.
- Traceability protocols to ensure efficient product tracking and potential recall procedures.
Under UK law, manufacturers and their Responsible Person must be able to demonstrate that the PMS activities are being carried out effectively and in accordance with current guidance. This includes generating Periodic Safety Update Reports (PSURs) where required, and responding to field safety corrective actions (FSCAs) promptly.
US companies may lack the infrastructure or regional personnel to meet UK PMS expectations. PMS findings must be fed back into the company’s quality management system (QMS) to support continuous improvement and corrective action planning. Failure to integrate these activities appropriately can result in regulatory findings during inspections or audit events.
Related Reading: Demystifying UK Medical Device Regulation: A Beginner’s Guide
4. Appointing an Ill-Equipped UK Responsible Person
One of the most significant post-Brexit regulatory requirements for non-UK manufacturers is the appointment of a UK-based Responsible Person (RP). This role is legally mandated and central to maintaining ongoing compliance with MHRA regulations.
The RP is responsible for:
- Ensuring the device is correctly registered with the MHRA.
- Confirming that the Declaration of Conformity and technical documentation are compliant and current.
- Cooperating with the MHRA for inspections, audits, or post-market investigations.
- Communicating safety issues, recalls, or adverse events as required by UK law.
Despite these critical responsibilities, many US manufacturers designate distributors or unrelated third parties without verifying regulatory qualifications or legal capacity. In some cases, the RP is appointed solely for logistical convenience rather than regulatory competence, resulting in poor document control, inadequate PMS procedures, and slow response times during inspections.
A poorly selected RP can jeopardise the manufacturer’s compliance status, disrupt market access, and create reputational risk. The MHRA treats the RP as a direct extension of the manufacturer, and any deficiencies in performance are taken seriously.
Manufacturers should conduct due diligence when selecting an RP, assessing technical expertise, responsiveness, and the ability to maintain secure documentation. Ideally, the RP should be a dedicated regulatory professional or consultant with strong knowledge of UK device law and the MHRA’s expectations.
5. Failure to Localise Operations and Compliance Systems
Compliance in the UK extends beyond product registration and documentation. US companies frequently underestimate the operational and cultural differences between FDA and MHRA expectations, particularly in labelling, language requirements, Instructions for Use (IFUs), and promotional practices.
Examples of overlooked UK-specific obligations include:
- Labelling that does not meet UK language or format requirements.
- Instructions for Use using US terminology or not reflecting local clinical practice.
- Documentation templates and technical files were built for FDA or EU submissions but did not meet UK format requirements.
- QMS assumes that ISO 13485 certification alone is sufficient, without integration of UK-specific regulatory control.
Related Reading: The Complete Guide to ISO 13485 Certification for Medical Device Companies
US manufacturers also tend to overlook UK-specific advertising and promotional guidance. Marketing materials, websites, and sales collateral must be reviewed to ensure that claims are supported by evidence and do not violate MHRA guidelines on misleading information or overstatement of clinical benefits.
Staff training, internal audits, and supplier management procedures must be adjusted to reflect UK MDR requirements. Quality systems should embed UK-specific compliance checks and reporting structures. Without these measures, manufacturers risk non-compliance during MHRA inspections or market surveillance visits.
Firms are encouraged to treat UK compliance as a separate regulatory domain, rather than an extension of their UA or EU systems. This approach improves clarity, reduces risk, and facilitates smoother communication with regulators.
Supporting Strategic Market Entry with Regulatory Insight
While the UK remains a strategically important market for US medical device firms, its post-Brexit regulatory landscape demands a tailored, proactive compliance strategy. Relying on an FDA-centric process or legacy EU submissions is no longer sufficient and can lead to costly delays, enforcement actions, or product recalls.
The most common mistakes in the MHRA approval process, including inaccurate submissions, insufficient PMS planning, and the appointment of underqualified Responsible Persons, are avoidable with the right preparation and regulatory oversight.
At Russell Regulatory Consultants, we help medical device manufacturers through the complexities of UK compliance with confidence. From technical files audited and MHRA registration support to UK Responsible Person services and PMS system setup, our expert team offers practical, end-to-end guidance. We understand where most companies stumble and how to prevent it.
If you’re planning to enter the UK market or need support with post-market obligations, contact us today to streamline your regulatory journey and avoid the most common compliance pitfalls.
Article Sources
- GOV.UK. “Using the UKCA marking.” 28 August 2025.
- GOV.UK “Regulating medical devices in the UK.” 28 August 2025.
- MHRA. “Medical devices: post-market surveillance requirements.” 28 August 2025.
- MHRA. “Register medical devices to place on the market.” 28 August 2025.
- ISO. “ISO 1345:2016.” 28 August 2025.
